5 results about "Dextran 40" patented technology

The application discloses an intelligent antibacterial hydrogel combined with a photosensitizer and an antibiotic as well as a preparation method and application thereof. The hydrogel takes oxidized dextran 40 as a hydrogel matrix, bonds 5-amino hexyl acetylpropionate into OAHAL through a Schiff base reaction, and is then crosslinked with amikacin to be prepared. The hydrogel has pH sensitivity, can effectively release drugs under an inflammatory slightly acidic environment, realizes on-demand release of the drugs, avoids overuse of the antibiotic, reduces toxic side effects, simultaneously loads two kinds of bactericidal drugs, 5-amino hexyl acetylpropionate and amikacin, and synergistically resists bacteria through two different mechanisms of photodynamic therapy and antibiotics, so that the antibacterial effect is significantly improved, and bacterial colonies caused by various types of wounds can be eliminated, and bacterial infection of a wound surface can be effectively prevented or treated.

The invention relates to a freezing medium and a freezing method for universal CAR (chimeric antigen receptor) cells. The cryopreservation liquid comprises a compound electrolyte injection, a human serum albumin injection, a sodium chloride injection, a dextran 40 glucose injection, a glucose injection, dimethyl sulfoxide and trehalose. The cell cryopreservation process is deeply analyzed, the specific cell cryopreservation liquid and the cryopreservation method are designed, all the components of the cryopreservation liquid are synergistic, the cryopreservation liquid can adapt to the specific cooling process, cell damage in the cryopreservation process is effectively reduced, the activity of the cryopreserved cells is effectively kept, the cryopreservation liquid can be directly used for reinfusion of patients, a specific sectional programmed cooling program is adopted, and the cell cryopreservation process is simplified. The cell cryopreservation device can further adapt to different cryopreservation volumes, so that the cryopreservation effect is further improved, the survival rate of cells is effectively guaranteed, and the cryopreserved cells still keep good cell activity.

Described herein are DMSO formulations and methods for cell therapy. Methods of treating a cell with these formulations are also provided. The embodiments provide a formulation that maintains the suspension and viability of a T-cell during cell therapy (CT) manufacturing and through a cryopreservation thaw cycle, including dimethyl sulfoxide (DMSO); sucrose or trehalose; human semm albumin (HSA); and dextran 40 or hydroxyethyl starch (HES). wherein the formulation maintains the suspension and viability of T-cells during CT manufacturing and through a cryopreservation thaw cycle. The embodiments provide a method for maintaining a suspension and cell viability, including subjecting a T-cell during a cell therapy manufacturing cryopreservation thaw cycle to a formulation including DMSO; sucrose or trehalose; human semm albumin (HSA); and polysaccharide or HES wherein the formulation maintains the suspension and viability of a T-cell during cell therapy manufacturing and through a cryopreservation thaw cycle.

The invention relates to the technical field of medicines, in particular to an L-4-boryl phenylalanine intravenous injection as well as a preparation method and application thereof. According to the L-4-boryl phenylalanine intravenous injection disclosed by the invention, a glucose-low molecular dextran complexing agent (in a mass ratio of (3-5): 1) or a maltitol-polyethylene glycol 400 complexing agent (in a mass ratio of (2-4): 1) is used as a solubilizer to replace saccharides such as D-sorbitol, fructose and the like used in the prior art. The composite solubilizer provided by the invention not only can significantly improve the solubility of L-BPA, but also can enhance the stability of a preparation, and realizes room temperature preservation. According to the preparation method, an integrated process of ultrasonic-assisted dissolution, buffer pair adjustment and nanofiltration infiltration reduction is adopted, a traditional sodium hydroxide-hydrochloric acid adjustment system is avoided, the pH value is accurately controlled through a citric acid-sodium dihydrogen phosphate buffer pair, excessive ions are removed in cooperation with a nanofiltration technology, and a salt-free preparation process is achieved.

The invention relates to the technical field of immune cells, and discloses a high-activity immune cell cryopreservation method and a high-activity immune cell recovery method. The cryopreservation protective agent is prepared from the following raw materials in percentage by volume: 8 to 12 percent of dimethyl sulfoxide, 5 to 8 percent of trehalose, 5 to 10 percent of dextran 40 to 60, 2 to 4 percent of human serum albumin, 0.1 to 0.5 percent of a cell factor mixture, 3 to 6 percent of an active protective agent and the balance of a basic culture medium. According to the invention, trehalose, dextran 40-60 and an active protective agent composed of a mitochondrial targeting antioxidant SS-31, a caspase inhibitor Z-VAD-FMK and membrane stability polypeptide are introduced, and the concentration and addition mode of dimethyl sulfoxide are strictly controlled, so that the damage of a traditional cryopreservation protective agent to cells due to osmotic pressure impact and chemical toxicity can be reduced.